Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsLin Li, Shirong Cai, Christine E. Ryan et al.|UNC Libraries|2020Cited by 19
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Laura J. Esserman, David M. Ota, Souzan Sanati et al.|UNC Libraries|2020Cited by 0